Literature DB >> 12235219

Targeting the epidermal growth factor receptor for cancer therapy.

John Mendelsohn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12235219

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  93 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

Authors:  Terrance G Johns; Rodney B Luwor; Carmel Murone; Francesca Walker; Janet Weinstock; Angela A Vitali; Rushika M Perera; Achim A Jungbluth; Elisabeth Stockert; Lloyd J Old; Edouard C Nice; Antony W Burgess; Andrew M Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

Review 3.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 4.  EGF receptors as a target for cancer therapy.

Authors:  John Mendelsohn
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

5.  Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.

Authors:  Yingmiao Liu; Chien-Tsun Kuan; Jing Mi; Xiuwu Zhang; Bryan M Clary; Darell D Bigner; Bruce A Sullenger
Journal:  Biol Chem       Date:  2009-02       Impact factor: 3.915

Review 6.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

7.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

8.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

Review 9.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

Review 10.  Chemotherapy for metastatic gastric cancer: past, present, and future.

Authors:  Atsushi Ohtsu
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.